2nd Quarter - Report

CROSSROADS STRATEGIES, LLC for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1227 (119th), S. 475 (119th)

Medical/Disease Research/Clinical Labs MED

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: S. 475 (119th), H.R. 1227 (119th)

Trade (domestic/foreign) TRD

Policies impacting the manufacturing pharmaceutical products including tariffs.

LobbyistCovered position, as disclosed
CHERYL LYNN JAEGER —
STEPHEN THOMAS VOLJAVEC —

Contacted: HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.